Effect of Metformin and Pyoglitazon on the Risk Factors of Cardiovascular Pathology Diagnosed During Screening of Patients With Type 2 Diabetes Mellitus
Year: 2016
Type: article
Abstract: Under assessment there was metformin and pyoglitazon effect on the risk factors of cardiovascular disease. During treatment of patients with screening-diagnosed type 2 diabetes mellitus, the following changes were noted: decreasing the levels of glycated hemoglobin, Willebrand factor and C-reactive protein, and increasing the level of HDL cholesterol. It was shown that 6-month-long therapy with metformin and pyoglItazon allowed significant improving glycemia control and influencing markers of cardiovascular risk in these patients.
Source: Almanac of Clinical Medicine
Authors: I. V. Misnikova, A. V. Dreval, T. S. Lakeeva
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W51657241